During type 2 inflammation in the lung, IL-13 is a significant driver of goblet cell responses (14), and our data provide evidence that IL-13 signaling is active in COVID-19 but less dramatic, histologically, than in other models of type 2 immunity (26, 27). This evidence concerns the gene IL13 and COVID-19.